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The aim of this study was to analyze the expectorant, antitussive and antiasthmatic effects of asterosa-
ponin from Luidia quinaria through secretion of phenol red from mouse tracheas, frequency of cough 
caused by ammonia in mice and asthma induced by histamine in guinea pig, respectively. Results 
showed that asterosaponin extracted from L. quinaria at doses of 20 mg/kg and 40 mg/kg could signi-
ficantly increase secretion of phenol red from mouse tracheas, prolonged the latent period of asthma 
induced by histamine, and decreased the frequency of cough caused by ammonia. In conclusion, 
asterosaponin from L. quinaria has obvious antitussive, antiasthmatic and expectorant effects.  
 





There has been extensive interest in the search for new 
biologically active compounds from natural sources over 
the last decade. Great attention has been paid to natural 
products from marine organisms such as echinoderms, 
sponges and ascidians and considerable interest current-
ly centers on their remarkable diversity of chemical struc-
tures and pharmacological activities (Kunetsova et al., 
1982; Findlay et al., 1987; Kitagawa and Kobayashi 1993; 
Krebs 1986). 
Substances with potent pharmacological effect and low 
toxicity are the most possible candidates for future clinical 
application. Steroidal glycosides are the predominant me-
tabolites of starfishes and are responsible for their toxi-
city. Structurally, these saponins can be divided into 3 
classes, asterosaponins, steroidal cyclic glycosides and 
glycosides of polyhydroxylated sterols. A broad variety of 
biological activities of starfish asterosaponins have been 
reported, among which are cytotoxic, hemolytic, antibac-
terial, antineoplastic, antifungal, antiviral properties, anti-
inflammatory effects and ichthyotoxic effect as well 
(Hashimoto et al. 1960; Faulkner et al., 1995; Guo et al., 
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et al., 1989). However, pharmacological effects of astero-
saponins such as expectorant, antitussive, antiasthmatic 
and other chronic bronchitis and respiratory diseases ha-
ve not been reported. 
In the present study, asterosaponins was isolated from 
starfish L. quinaria and its structure elucidated on the 
basis of extensive spectroscopic experiments and chemi-
cal correlations. The bioactivities of asterosaponins such 
as expectorant, antitussive and antiasthmatic were eval-
uated according to national new drug pharmacological 
experiment standards. The results will provide pharmaco-
logical groundwork for application of asterosaponins in 
chronic bronchitic diseases. 
 
 
MATERIALS AND METHODS 
 
Chemicals and materials 
 
Asterosaponin was extracted from starfish L. quinaria. Positive con-
trol drugs such as acute bronchitis syrup, NH4Cl tablet, codeine 
phosphate and aminophylline tablets were obtained from pharma-
ceutical factory in China. Phenol red, ammonia, histamine, acetyl-
choline and other chemicals were at analytical grade and were pur-










Table 1. Effects of asterosaponin on phenol red secretion 
from mouse tracheas. 
 
Groups Doses O.D 
Control 10 ml/kg 0.042 ± 0.012 
Acute bronchitis syrup  15 ml/kg 0.044 ± 0.017 
Asterosaponin 20 mg/kg 0.063 ± 0.011* 
Asterosaponin 40 mg/kg 0.081±0.014** 
NH4Cl 1000mg/kg 0.052 ± 0.020 
 




from pharmacological laboratories of Yantai university, barrier hous-
ed in a clean environment with access to water and food ad libitum 
and kept in a temperature-controlled environment maintained on a 
12 h cycle. The colony was free of pathogens. The experiment was 
done according to the experimental animal committee regulations. 
 
 
Assay of expectorant effects 
 
5 groups of Kunming mice (n = 10 for each group) were used in this 
assay. The control group was treated with saline. Acute bronchitis 
syrup (15 ml/kg), asterosaponin (20 mg/kg), asterosaponin (40 
mg/kg) and NH4Cl (1000 mg/kg) were administrated intragatrically 
to mice of experimental groups respectively for 7 consecutive days 
except NH4Cl group, which was only treated on the 7th day. Phenol 
red was prepared in saline with final concentration of 2.5% and in-
jected intraperitoneally (0.2 ml/10 g) 60 min after last administration. 
Mice were then sacrificed by cervical decapitation 30 min after phe-
nol red injection. Trachea was then dissected out and placed in 1 ml 
saline. After 10 min, the solution was mixed with 0.1 ml NaOH 
(1mol/L) and absorbance at 570 nm was measured on BIORAD 
Model 550 microplate reader.  
 
 
Assay of cough caused by ammonia 
 
Male and female mice were randomized into 4 groups with 10 ani-
mals for each group. One group of animals treated with saline was 
kept as control. Codeine phosphate group was treated with codeine 
phosphate (5 mg/kg) intragastrically for 3 consecutive days and the 
other 2 groups were treated with different doses of asterosaponin 
intragastrically (20 mg/kg, 40 mg/kg) for 3 consecutive days res-
pectively. On the 3rd day, 60 min after drug administration, mice 
were exposed to irritant agent, ammonia, for 5 s using an ultrasonic 
nebulizer (PARIMASTER) via whole body exposure. Latent period 
of cough (S, from exposure to first cough) and times of cough du-
ring 2 min period were recorded.  
 
 
Assay of asthma induced by histamine  
 
Guinea pigs with latent period of asthma within 150 s were chosen 
for this study. Guinea pigs were randomly divided into 4 groups with 
10 animals for each group.  The  control  animals  were  pretreated  
with vehicle (saline 0.9%). Animals of the other 3 groups were pre-
treated with aminophylline (125 mg/kg), asterosaponin (20 mg/kg) 
and asterosaponin (40 mg/kg) intragastrically for 3 consecutive 
days, respectively. One hour after last administration, guinea pigs 
were exposed to irritant agent, histamine and acetylcholine mixture, 
for 20 s using an ultrasonic nebulizer (PARIMASTER) via whole 
body exposure. Latent periods of asthma were recorded. 






Data were expressed as mean ± S.D. Differences between groups 
were analyzed by students’ unpaired t-test for individual compari-
sons and by one-way analysis of variance (ANOVA). Differences 
were considered significant when P < 0.05 and very significant 
when P < 0.01.  
 
 
RESULTS AND DISCUSSION  
 
Expectorant effect of asterosaponin 
 
Asterosaponin significantly increased phenol red secre-
tion from mice tracheas by 50 and 90% of control at 
doses of 20 and 40 mg/kg respectively (Table 1). Our re-
sults indicated that asterosaponin had a strong expec-
torant effect and provided pharmacological data-base for 
further application of asterosaponin in chronic bronchitis 
and other respiratory diseases therapeutics.  
 
 
Antitussive effects of asterosaponin 
 
As shown in Table 2, the antitussive effects of asterosa-
ponin on mice was examined by the frequency of cough 
caused by ammonia and the latent period of cough after 
administration. Asterosaponin at dose of 20 mg/kg could 
prolong the latent period of cough by 12% and signifi-
cantly decreased coughing time by 15% within 2 min 
when compared to control (P < 0.05). Asterosaponin at 
dose of 20 mg/kg could prolong the latent period of cough 
by 26% and dramatically decrease cough time by 33% 
within 2 min when compared to control (P < 0.01). This 
suggested that asterosaponin has a strong anti-tussive 
effect.   
 
 
Antiasthmatic effects of asterosaponin 
 
We also tested the effects of asterosaponin on the latent 
period of asthma caused by histamine (Table 3). Our re-
sults show that asterosaponin could significantly prolong 
the latent period of asthma induced by histamine and this 
prolongation was dose-dependent. The latent period of 
asthma was significantly increased by 29% (P < 0.05) 
and 49% (P < 0.01) at dose of 20 and 40 mg/kg respect-





Chronic respiratory system diseases, although not life- 
threatening, can cause general debility, weakness and 
social embarrassment, which contribute to deterioration 
in quality of life. More recent epidemiological surveys ha-
ve provided data that currently available antitussives for 
both acute and chronic cough are not very effective and 
that   there   is    an   unmet   need    of    more    effective   




Table 2. Effects of asterosaponin on cough caused by ammonia. 
 
Groups Doses (ml/kg) Latent period of cough Cough times 
Prior drugs After drugs Prior drugs After drugs 
Control NS 24.5 ± 3.4 25.1± 2.8 21.7 ± 3.1 20.3 ± 6.4 
Codeine  5 mg/kg 24.0 ± 3.7 28.4 ± 2.3 21.0 ± 3.6 13.1 ± 5.9* 
Phosphate  20 mg/kg 24.8 ± 3.0 28.0 ± 3.0 21.8 ± 3.7 17.2 ± 4.2* 
Asterosaponin 40 mg/kg 25.0 ± 2.6 31.7 ± 5.0 25.0 ± 2.7 13.7 ± 3.5** 
 
Values presented as the mean ± S.D. (n=10). 




Table 3. Effects of asterosaponin on latent period of 
asthma caused by histamine. 
 
Groups Doses Latent period of 
asthma(s) 
Control NS 54.1±14.9 
Aminophylline  125 mg/kg 83.3±12.1** 
Asterosaponin 20 mg/kg 69.8 ± 8.2* 
Asterosaponin 40 mg/kg 80.4±14.9** 
 





Our studies showed that asterosaponin extracted from 
L. quinaria had excellent antitussive, antiasthmatic and 
expectorant properties. Although further studies are 
needed to better evaluate its activities and its mechani-
sm(s), our data suggest that asterosaponin might be a 
candidate for the therapeutics of chronic bronchitis and 
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